These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27543192)

  • 1. Horizontal melanonychia.
    Salman A; Eser A; Kaygusuz Atagunduz I; Ergun T
    Actas Dermosifiliogr; 2017 Jun; 108(5):469-470. PubMed ID: 27543192
    [No Abstract]   [Full Text] [Related]  

  • 2. Nail changes in a patient with leukaemia.
    Bhaskar ME
    BMJ; 2011 Jan; 342():c6439. PubMed ID: 21224311
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Shi CR; Nambudiri VE
    Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
    Thapa M; Chaturvedi A
    Postgrad Med J; 2020 May; 96(1135):296-297. PubMed ID: 31672761
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
    Steele JC; Triantafyllou A; Rajlawat BP; Field EA
    Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 8. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 9. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
    McGrath K; Stein B; Kalhagen L; Leighton L
    Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
    [No Abstract]   [Full Text] [Related]  

  • 11. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM; Lam YK; Leung KH; Lin SY
    Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
    Wong M; Sade S; Gilbert M; Klieb HB
    Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
    Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
    Eşkazan AE
    Br J Clin Pharmacol; 2020 Sep; 86(9):1790-1792. PubMed ID: 32383276
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
    Yu YH; Shere Y; Vigneswaran N
    Tex Dent J; 2012 Aug; 129(8):764-5, 786-8. PubMed ID: 22988661
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of hydroxyurea-induced longitudinal melanonychia.
    Utaş S; Kulluk P
    Int J Dermatol; 2010 Apr; 49(4):469-70. PubMed ID: 20465711
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia.
    Yun S; Vincelette ND; Abraham I
    JAMA Oncol; 2016 Jun; 2(6):828-9. PubMed ID: 27281623
    [No Abstract]   [Full Text] [Related]  

  • 19. Should vascular effects of newer treatments be addressed more completely?
    Yang EH; Watson KE; Herrmann J
    Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
    Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
    Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.